Results 111 to 120 of about 3,380,570 (289)

STAINING TOXOPLASMA GONDII WITH FLUORESCEIN-LABELLED ANTIBODY [PDF]

, 1957
Morris Goldman
openalex   +1 more source

Author Correction: A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques

npj Vaccines, 2023
Ting Bian, Meng Hao, Xiaofan Zhao, Chuanyi Zhao, Gang Luo, Zhendong Zhang, Guangcheng Fu, Lu Yang, Yi Chen, Yudong Wang, Changming Yu, Yilong Yang, Jianmin Li, Wei Chen   +13 more
doaj   +1 more source

Studies on the Adjuvant Action of Bacterial Endotoxins on Antibody Formation [PDF]

, 1959
Phyllis D. Kind, Arthur G. Johnson
openalex   +1 more source

The Production of Antibodies (2nd Edition) [PDF]

, 1951

openalex   +1 more source

New Rh Antibody [PDF]

, 1953
A.S. Wiener
openalex   +1 more source

Antibodies, repertoires and microdevices in antibody discovery and characterization

Lab on a Chip
Essential in treating numerous diseases, novel therapeutic antibody candidates are needed. This critical review examines recent advances in microdevices and the challenges associated with candidate discovery and characterization.
Luca Johannes Schlotheuber, Ines Lüchtefeld, Klaus Eyer   +2 more
openaire   +4 more sources

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice

Vaccines
Background: Cervical cancer ranks as the fourth most common cancer affecting women globally, with HPV as the primary etiology agent. Prophylactic HPV vaccines have substantially reduced the incidence of cervical cancer.
Lei Bei, Shuman Gao, Dandan Zhao, Yajuan Kou, Siyu Liang, Yurong Wu, Xiao Zhang, Dan Meng, Jianbo Lu, Chunxia Luo, Xuefeng Li, Yang Wang, Hongbin Qiu, Liangzhi Xie   +13 more
doaj   +1 more source

Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody

Pharmaceuticals
Background/Objectives: Finotonlimab (SCTI10A) is a humanized anti-PD-1 antibody tested in Phase III trials for several solid tumor types. Methods: This study characterized the in vitro and in vivo efficacy, Fc-mediated effector function, and non-clinical
Yunqi Yao, Xiaoning Yang, Jing Li, Erhong Guo, Huiyu Wang, Chunyun Sun, Zhangyong Hong, Xiao Zhang, Jilei Jia, Rui Wang, Juan Ma, Yaqi Dai, Mingjing Deng, Chulin Yu, Lingling Sun, Liangzhi Xie   +15 more
doaj   +1 more source

Protein-environment-sensitive computational epitope accessibility analysis from antibody dose-response data [PDF]

arXiv
Antibodies are widely used in life-sciences and medical therapy. Yet, broadly applicable methods are missing to determine, in the biological system of choice, antibody specificity and its quantitative contribution to e.g. immunofluorescence stainings. Thereby, antibody-based data often needs to be seen with caution.
arxiv  

Modelling the effect of antibody depletion on dose-response behavior for common immunostaining protocols [PDF]

arXiv
Dose-response curves of immunostaining experiments are commonly described as Langmuir isotherm. However, for common immunostaining protocols the equilibrium assumption is violated and the dose-response behavior is governed by antibody accumulation. If bound antibodies are replenished, i.e.
arxiv